These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8767842)

  • 1. Non-nucleoside anti-HIV-1 reverse transcriptase inhibitors (NNRTIs): a chemical survey from lead compounds to selected drugs for clinical trials.
    Artico M
    Farmaco; 1996 May; 51(5):305-31. PubMed ID: 8767842
    [No Abstract]   [Full Text] [Related]  

  • 2. Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors.
    Cushman M; Golebiewski WM; Graham L; Turpin JA; Rice WG; Fliakas-Boltz V; Buckheit RW
    J Med Chem; 1996 Aug; 39(16):3217-27. PubMed ID: 8759644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development.
    de Clercq E
    Med Res Rev; 1996 Mar; 16(2):125-57. PubMed ID: 8656777
    [No Abstract]   [Full Text] [Related]  

  • 4. Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones: novel and specific non-nucleoside HIV-1 reverse transcriptase inhibitors with antiviral activity.
    Campiani G; Nacci V; Fiorini I; De Filippis MP; Garofalo A; Greco G; Novellino E; Altamura S; Di Renzo L
    J Med Chem; 1996 Jul; 39(14):2672-80. PubMed ID: 8709096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors.
    Auwerx J; Esnouf R; De Clercq E; Balzarini J
    Mol Pharmacol; 2004 Jan; 65(1):244-51. PubMed ID: 14722257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors.
    Dollé V; Fan E; Nguyen CH; Aubertin AM; Kirn A; Andreola ML; Jamieson G; Tarrago-Litvak L; Bisagni E
    J Med Chem; 1995 Nov; 38(23):4679-86. PubMed ID: 7473595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-atom models for the non-nucleoside binding site of HIV-1 reverse transcriptase complexed with inhibitors: a 3D QSAR approach.
    Gussio R; Pattabiraman N; Zaharevitz DW; Kellogg GE; Topol IA; Rice WG; Schaeffer CA; Erickson JW; Burt SK
    J Med Chem; 1996 Apr; 39(8):1645-50. PubMed ID: 8648604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of NNRTIs on HIV reverse transcriptase dimerization.
    Tachedjian G; Goff SP
    Curr Opin Investig Drugs; 2003 Aug; 4(8):966-73. PubMed ID: 14508881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Highly specific inhibitors of human immunodeficiency virus type I that are particularly targeted at the reverse transcriptase].
    de Clercq E; Snoeck R
    Pathol Biol (Paris); 1993 Mar; 41(3):230-6. PubMed ID: 7687340
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimization of 5-aryloxyimidazole non-nucleoside reverse transcriptase inhibitors.
    Jones LH; Allan G; Corbau R; Hay D; Middleton DS; Mowbray CE; Newman SD; Perros M; Randall A; Vuong H; Webster R; Westby M; Williams D
    ChemMedChem; 2008 Nov; 3(11):1756-62. PubMed ID: 18855969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric inhibitors against HIV-1 reverse transcriptase: design and synthesis of MKC-442 analogues having an omega-functionalized acyclic structure.
    Tanaka H; Walker RT; Hopkins AL; Ren J; Jones EY; Fujimoto K; Hayashi M; Miyasaka T; Baba M; Stammers DK; Stuart DI
    Antivir Chem Chemother; 1998 Jul; 9(4):325-32. PubMed ID: 9875411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
    Chan JH; Freeman GA; Tidwell JH; Romines KR; Schaller LT; Cowan JR; Gonzales SS; Lowell GS; Andrews CW; Reynolds DJ; St Clair M; Hazen RJ; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Koszalka GW; Boone LR
    J Med Chem; 2004 Feb; 47(5):1175-82. PubMed ID: 14971897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of N-acetyl-beta-aryl-1,2-didehydroethylamines as new HIV-1 RT inhibitors in vitro.
    Cheng P; Jiang ZY; Wang RR; Zhang XM; Wang Q; Zheng YT; Zhou J; Chen JJ
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4476-80. PubMed ID: 17574419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
    Piscitelli F; Coluccia A; Brancale A; La Regina G; Sansone A; Giordano C; Balzarini J; Maga G; Zanoli S; Samuele A; Cirilli R; La Torre F; Lavecchia A; Novellino E; Silvestri R
    J Med Chem; 2009 Apr; 52(7):1922-34. PubMed ID: 19281225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
    Hopkins AL; Ren J; Milton J; Hazen RJ; Chan JH; Stuart DI; Stammers DK
    J Med Chem; 2004 Nov; 47(24):5912-22. PubMed ID: 15537346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.
    Heeres J; de Jonge MR; Koymans LM; Daeyaert FF; Vinkers M; Van Aken KJ; Arnold E; Das K; Kilonda A; Hoornaert GJ; Compernolle F; Cegla M; Azzam RA; Andries K; de Béthune MP; Azijn H; Pauwels R; Lewi PJ; Janssen PA
    J Med Chem; 2005 Mar; 48(6):1910-8. PubMed ID: 15771435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations.
    Tucker TJ; Saggar S; Sisko JT; Tynebor RM; Williams TM; Felock PJ; Flynn JA; Lai MT; Liang Y; McGaughey G; Liu M; Miller M; Moyer G; Munshi V; Perlow-Poehnelt R; Prasad S; Sanchez R; Torrent M; Vacca JP; Wan BL; Yan Y
    Bioorg Med Chem Lett; 2008 May; 18(9):2959-66. PubMed ID: 18396399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.
    Tucker TJ; Sisko JT; Tynebor RM; Williams TM; Felock PJ; Flynn JA; Lai MT; Liang Y; McGaughey G; Liu M; Miller M; Moyer G; Munshi V; Perlow-Poehnelt R; Prasad S; Reid JC; Sanchez R; Torrent M; Vacca JP; Wan BL; Yan Y
    J Med Chem; 2008 Oct; 51(20):6503-11. PubMed ID: 18826204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
    Pelemans H; Aertsen A; Van Laethem K; Vandamme AM; De Clercq E; Pérez-Pérez MJ; San-Félix A; Velázquez S; Camarasa MJ; Balzarini J
    Virology; 2001 Feb; 280(1):97-106. PubMed ID: 11162823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 7. 8-Arylethyldipyridodiazepinones as potent broad-spectrum inhibitors of wild-type and mutant enzymes.
    Klunder JM; Hoermann M; Cywin CL; David E; Brickwood JR; Schwartz R; Barringer KJ; Pauletti D; Shih CK; Erickson DA; Sorge CL; Joseph DP; Hattox SE; Adams J; Grob PM
    J Med Chem; 1998 Jul; 41(16):2960-71. PubMed ID: 9685235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.